2 recruiting, 1 active not recruiting, 1 unknown, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Refractory Colorectal Adenocarcinoma: new trials by email Literature Review of Refractory Colorectal Adenocarcinoma trials Research Report on Refractory Colorectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-09-23 |
| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer Pembrolizumab, Questionnaire Administration, Rintatolimod - Metastatic Colorectal Adenocarcinoma, Microsatellite Stable | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2022-02-01 | 2022-02-08 | |
| caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer. Cabozantinib - Refractory Colorectal Adenocarcinoma | Phase 2 | Unknown | University of Campania Luigi Vanvitelli | 33 | 2019-09-01 | 2024-01-02 |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Laboratory Biomarker Analysis, Panitumumab, Trametinib - EGFR NP_005219.2:p.S492R, KRAS Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 59 | 2017-12-29 | 2026-07-16 |
Colorectal Neoplasms (4) · Colonic Neoplasms (1)
Colonic Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Rectal Diseases (4) · Colorectal Neoplasms (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · (225)Ac-DOTA-c(RGDyK) (1) · CX 5461 (1) · Cetuximab (1) · Panitumumab (1) · cabozantinib (1) · cemiplimab (1) · encorafenib (1) · pembrolizumab (1) · poly(I).poly(c12,U) (1) · trametinib (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Campania Luigi Vanvitelli (1)
United States (4) · Italy (1)
Christine Parseghian (1) · Christos Fountzilas, MD (1) · Erika Martinelli, MD, PhD (1) · Salvador Alonso Martinez (1) · Wells A Messersmith (1)
UM1CA186688 (1), UM1CA186691 (1)